{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T12:00:19Z","timestamp":1768132819330,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00277-023-05231-4","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:05:09Z","timestamp":1682510709000},"page":"1599-1600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed\/refractory T-cell acute lymphoblastic leukemia patient"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-8068","authenticated-orcid":false,"given":"S\u00fcreyya","family":"Yi\u011fit Kaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-1536","authenticated-orcid":false,"given":"Sebnem","family":"Bektas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-0335","authenticated-orcid":false,"given":"Abdullah Emre","family":"Askin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-7818","authenticated-orcid":false,"given":"Berrin","family":"Bal\u0131k Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-2822","authenticated-orcid":false,"given":"Ya\u015fa G\u00fcl","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-4113","authenticated-orcid":false,"given":"\u00d6m\u00fcr G\u00f6kmen","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"9","key":"5231_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks DI, Rowntree C (2017) Management of adults with T-cell lymphoblastic leukemia. Blood 129(9):1134\u20131142","journal-title":"Blood"},{"issue":"13","key":"5231_CR2","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M et al (2021) Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma 62(13):3300\u20133303","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"5231_CR3","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni A, Lazzarotto D, Ferrara F et al (2020) Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol 95(12):1466\u20131472","journal-title":"Am J Hematol"},{"issue":"8","key":"5231_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/17474086.2021.1960817","volume":"14","author":"DW Baek","year":"2021","unstructured":"Baek DW, Lee JM, Kim J et al (2021) Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed\/refractory adult T-cell acute lymphoblastic leukemia. Expert Rev Hematol 14(8):765\u2013775","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"5231_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ et al (2020) Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"5231_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS et al (2021) Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther 14(3):246\u2013251","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"5231_CR7","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1097\/HS9.0000000000000379","volume":"4","author":"A McEwan","year":"2020","unstructured":"McEwan A, Pitiyarachchi O, Viiala N (2020) Relapsed\/refractory ETP-ALL successfully treated with venetoclax and nelarabine as a bridge to allogeneic stem cell transplant. HemaSphere 4(3):e379","journal-title":"HemaSphere"},{"issue":"7","key":"5231_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/14740338.2021.1919621","volume":"20","author":"A Candoni","year":"2021","unstructured":"Candoni A, Lazzarotto D, Petruzzellis G (2021) Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia\/lymphoma. Expert Opin Drug Saf 20(7):751\u2013756","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"5231_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00277-022-04880-1","volume":"101","author":"M Kathpalia","year":"2022","unstructured":"Kathpalia M, Mishra P, Bajpai R et al (2022) Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Ann Hematol 101(8):1655\u20132166","journal-title":"Ann Hematol"},{"issue":"7","key":"5231_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","volume":"79","author":"YA Heo","year":"2019","unstructured":"Heo YA, Syed YY, Keam SJ (2019) Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs 79(7):767\u2013777","journal-title":"Drugs"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05231-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05231-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05231-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:18:45Z","timestamp":1683886725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05231-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5231"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05231-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for publication was obtained from the patient. All the authors have reviewed the manuscript and approved it for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}